
    
      Fremanezumab is indicated for patient suffering from Episodic or Chronic Migraine.

      Patients interested in received expanded access to Fremanezumab must meet the following
      conditions:

        1. Have participated in, and successfully completed, one of the two clinical studies
           TV48125-CNS-30051 (HALO) or TV48125-CNS-30068 (FOCUS)

        2. Participated from one of the following countries:

             1. For HALO: Canada, Czech Republic, Spain or Finland

             2. For FOCUS: Czech Republic, Spain, Finland, Germany, Sweden, Denmark, Netherlands,
                Italy, France or Belgium Eligible patients should contact their study physician to
                request expanded access.
    
  